2019³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö : 2019-10-25±³À°ÀÏÀÚ : 2019-10-25
±³À°Àå¼Ò : ¼¿ïµå·¡°ï½ÃƼȣÅÚ 3Ãþ ÇѶóȦ1,2
±³À°ÁÖÁ¦ :
2019³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸
´ã´çÀÚ : ½ÉÇöÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ: 5¸¸¿ø, Àü°øÀÇ, ÀüÀÓÀÇ: 2¸¸¿ø ÇöÀåµî·Ï: Àü¹®ÀÇ: 6¸¸¿ø, Àü°øÀÇ, ÀüÀÓÀÇ: 3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-25 ÇѶóȦ1 09:30~09:50 Immuno-oncology as a single therapy È«¼÷Èñ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 09:50~10:10 Immuno-chemotherapy as combination therapy ¼±Á¾¹«(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 10:10~10:30 Immuno-immunotherapy as combination therapy °ÀºÁÖ(°í·Á´ëÇб³º´¿ø)
Åä·Ð 10-25 ÇѶóȦ1 10:30~11:00 Case Presentation and Panel Discussion ()
ÈÞ½Ä 10-25 ÇѶóȦ1 11:00~11:15 ÈÞ½Ä ()
±³À°½Ã°£ 10-25 ÇѶóȦ1 11:15~11:35 Adjuvant or NeoAdjuvant Immumotherapy È«¹ÎÈñ(¿¬¼¼¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 11:35~11:55 Concurrent or Consolidation Immunotherapy: Radiation Oncologist View ¼Û½Ã¿(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 10-25 ÇѶóȦ1 11:55~12:15 Case Presentation and Panel Discussion ()
±³À°½Ã°£ 10-25 ÇѶóȦ1 12:15~13:15 Luncheon Symposium TBA()
±³À°½Ã°£ 10-25 ÇѶóȦ1 13:15~13:35 PD-L1 or Immune Biomarker ±èÈ¿Áø(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 13:35~13:55 Tumor Mutation Burden or Genetic Biomarker À̼¼ÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 13:55~14:15 Case Presentation and Panel Discussion È«¹ÎÈñ(¿¬¼¼¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 14:15~14:35 Response Evaluation: RECIST or irRECIST or iRECIST? ¾ÈÈñ°æ(°¡Ãµ´ë±æº´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 14:35~14:55 Progression, Hyper or Pseudo? À±½Å±³(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 10-25 ÇѶóȦ1 14:55~15:15 Case Presentation and Panel Discussion ()
ÈÞ½Ä 10-25 ÇѶóȦ1 15:15~15:40 ÈÞ½Ä ()
±³À°½Ã°£ 10-25 ÇѶóȦ1 15:40~16:00 Nivolumab: Real world experience from Expanded Access Program ÀÓ¼±¹Î(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 10-25 ÇѶóȦ1 16:00~16:20 Immunotherapy: from Health Insurance Review and Accessment ¹ÚÁöÇö(°Ç±¹´ëº´¿ø)
Åä·Ð 10-25 ÇѶóȦ1 16:20~16:50 Panel Discussion ()